Inotrem S.A.: Strategic Analysis of Precision Immunotherapy and European Health Autonomy
Strategic audit of Inotrem’s TREM-1 immunotherapy platform. Evaluating TRL 7 medical countermeasures for European biothreat preparedness and health sovereignty.
13 pages · PDF · 30 December 2025 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Inotrem S.A. is a Paris- and Nancy-based clinical-stage biotech company specializing in immunomodulatory therapies for acute inflammatory diseases. Its proprietary platform targets the TREM-1 immune receptor – a key amplifier of inflammation – aiming to restore balanced immune responses in life-threatening conditions .
The company’s flagship drug, nangibotide (INO-01), is a first-in-class peptide inhibitor of TREM-1 under Phase 2 trial evaluation for septic shock and severe COVID-19 . This precision-medicine approach (with a companion sTREM-1 diagnostic developed with Roche) exemplifies European innovative potential in biotechnology.
Key questions this report answers
- What immunotherapy capability does Inotrem develop through its TREM-1-targeting platform?
- How mature is its lead drug nangibotide (INO-01) in Phase 2 trials for septic shock and severe COVID-19?
- How do partnerships (e.g. the Roche companion sTREM-1 diagnostic) support its precision-medicine strategy?
- What capability gaps and dependencies face this Paris/Nancy clinical-stage biotech?
Inside this report
- Executive Summary
- Corporate Identity & Legal Structure
- Strategic Business Profile
- Technology Portfolio Mapping
- Technology Readiness Assessment
- European Strategic Program Participation
- Academic & Research Origins
- Dual-Use Applications & European Market Strategy
- Strategic Partnerships & European Industrial Alliances
- European Market Focus & Operational Domains
- Intellectual Property & European Innovation Assets
- Leadership & European Technical Expertise
- Capability and Gap Analysis
- Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Inotrem S.A., competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (30 December 2025). You receive a 13-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · Free summary of this report · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →